18 results about "Skeletal muscle cell" patented technology

Provided herein are compositions comprising a muscle (cardiac and / or skeletal) cell targeting peptide linked to or inserted into a targeting protein of a recombinant vector having at least one exogenous peptide comprising Xn-RGD-n-mer-Xm. Compositions providing such conjugates, targeting peptides, or recombinant vectors with engineered capsid or envelope proteins are provided, along with uses thereof.

The invention discloses a compound enzyme preparation-containing nutritional feed for regulating and controlling intramuscular fat of black pigs and a preparation method of the compound enzyme preparation-containing nutritional feed, and relates to the technical field of livestock and poultry breeding feeds. The invention discloses a black pig skeletal muscle cell fat directional transport feed which is prepared from the following components in parts by weight: 850-920 parts of basal feed, 5-12 parts of fat directional deposition compound enzyme group, 25-40 parts of amino acid-enzymatic synthesis substrate combination and 2-6 parts of lipolytic enzyme specific inhibitor. According to the black pig skeletal muscle cell fat directional transport feed, fat precursor directional transport is realized through the compounded fat directional deposition compound enzyme group, a fat synthesis pathway targeting black pig skeletal muscle cells and lipoprotein lipase; acetyl-coenzyme A carboxylase and fatty acid synthetase catalyze fat synthesis step by step, only intramuscular fat generation pathways are activated, subcutaneous and abdominal fat deposition paths are blocked, the technical defects that fat deposition of an existing single enzyme preparation is non-directional, and the body fat rate is caused to be abnormally increased are overcome, meanwhile, an exclusive amino acid-enzymatic synthesis substrate combination is matched, and the body fat synthesis efficiency is improved. Sufficient adaptive substrates are supplied to enzyme group catalytic reaction, and the problem that a single enzyme preparation is insufficient in catalytic efficiency is solved.

The invention relates to application of an FGFBP2 gene in regulation and control of growth and development and cell cycle of chicken skeletal muscle. The inventor finds the existence of the FGFBP2 gene in early-stage work of a team, and also finds that the expression quantity difference of the gene in muscular tissues of chickens in different development stages and varieties is obvious. In order to further reveal the effect of the FGFBP2 gene in the growth and development process of chicken skeletal muscles, the FGFBP2 gene is overexpressed in chicken myoblasts and AA broiler chickens respectively by using an overexpression technology, and detection finds that the overexpressed FGFBP2 gene can promote the proliferation of myoblasts. The discovery that the FGFBP2 gene can regulate and control the proliferation function of the chicken skeletal muscle cells provides a new theoretical basis for revealing the development of the chicken skeletal muscle and improving the meat production character, and provides a new thought for improving the meat production performance of livestock.

The present invention relates to a composition comprising sialyloligosaccharide and N-acetylmannosamine for the treatment of GNE myopathy, and a method of using same. Despite ManNac exhibiting non-significant sialylation activity in GNE knockdown (GNE KD) C2C12 skeletal muscle cells, it was confirmed that co-administration of ManNac and sialyloligosaccharide promotes sialylation more effectively than single administration, thereby exhibiting an excellent synergistic effect. Such effects have also been confirmed in an animal model of GNE myopathy, and thus the combined therapy of ManNAc and sialyloligosaccharide of the present invention is expected to be advantageously employed as a novel therapeutic approach capable of overcoming hyposialylation caused by sialic acid deficiency in GNE myopathy.

The application discloses a use and application based on CDKN1A influence on proliferation and differentiation of goat skeletal muscle, relates to the field of agricultural genetic engineering, and discloses that iRNA-seq and RNA-seq technology reveals mRNA expression maps of the longest dorsal muscle of 5-month-old Hainan black goats and 24-month-old Hainan black goats in two development stages, and CDKN1A with differential expression is screened out; the CDKN1A gene is used for negatively regulating proliferation of goat myoblasts; and the application finds that CDKN1A has a regulation effect on proliferation and differentiation of skeletal muscle cells of Hainan black goats, and can be applied to development and utilization of germplasm resources of the breed and seed selection and breeding.

This invention relates to an immortalized chicken skeletal muscle satellite cell line, its construction method, and its applications, belonging to the field of biotechnology. The immortalized chicken skeletal muscle satellite cell line Im MSLC of this invention, with accession number CCTCC NO: C2023115, was deposited on July 5, 2023, at the China Center for Type Culture Collection, located at No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province, Wuhan University. The immortalized chicken skeletal muscle satellite cell line of this invention maintains a similar growth rate and consistent growth trend to primary chicken skeletal muscle cells after 10 passages, and retains the same cell morphology as primary cells after 22 passages; moreover, the immortalized chicken skeletal muscle satellite cell line still possesses differentiation ability after 10 passages. The immortalized chicken skeletal muscle satellite cell line provided by this invention reduces the use of chicken embryos and lowers the possibility of difficulty in obtaining stable and reliable results due to different batches of chicken embryos from which skeletal muscle cells are derived.

The present application discloses the use of SUR2 receptor modulators. In the present application, SUR2 receptor modulators (e.g. MLC1) can be combined with skeletal muscle cell K ATP SUR2 specific binding on potassium ion channel, thus enhancing intracellular calcium signal, increasing glucose uptake of skeletal muscle cell and reducing blood glucose, and thus can be used as a therapeutic drug for diabetes; SUR2 receptor modulators selectively bind to SUR2 through a non-islet β cell dependent mechanism, and have no inhibitory effect on islet β cell SUR1 receptor, and thus can effectively avoid hypoglycemia while reducing blood glucose, and have small side effects.

This invention relates to the application of *Hirudo medicinalis* in the preparation of drugs that promote skeletal muscle cell differentiation and / or prevent muscle atrophy, belonging to the field of biomedical technology. The skeletal muscle cells are myoblasts. In vitro, this drug can promote differentiation by upregulating the expression of myosin heavy chain (MyHC), myogenin, and myogenic determinant MyoD, thereby increasing myotube diameter. In vivo, it can improve doxorubicin-induced skeletal muscle atrophy in mice and repair muscle fiber damage caused by natural aging nematodes. The chemotherapeutic drug is doxorubicin, which can exert an anti-atrophy effect by maintaining the expression of myosin heavy chain (MyHC) and improving myotube morphology damage. This invention is the first to discover and experimentally demonstrate that *Hirudo medicinalis* freeze-dried powder has the activity of promoting myoblast differentiation and preventing muscle atrophy, opening up new applications for traditional Chinese medicine leeches in the prevention and treatment of muscle atrophy and expanding the medicinal value of *Hirudo medicinalis*.

The invention discloses a traditional Chinese medicine composition for enhancing functions of mature skeletal muscle cells and application of the traditional Chinese medicine composition. The composition is prepared from ginseng, astragalus membranaceus, pericarpium citri reticulatae, dogwood and rhizoma polygonati according to a specific ratio. The invention also provides an establishment method based on the quality standard of various active components (ginsenoside Rg1, hesperidin and the like) in the composition. The traditional Chinese medicine composition disclosed by the invention does not have a remarkable activity promoting effect on undifferentiated C2C12 myoblasts in a proliferation period, but can specifically enhance the cell activity of differentiated mature C2C12 myotubular cells. The action characteristics of the cell state dependence show that the composition does not simply stimulate cell proliferation, but is targeted to improve the functional state of mature muscle cells, so that a high-precision solution is provided for treating diseases (such as sarcopenia) characterized by mature muscle fiber function decline.

The invention discloses a medicinal and edible composition for improving muscle attenuation of old people, the composition comprises fructus piperis longi and radix asparagi extracts, and the composition is combined with highland barley, common turnip, maca, D-psicose and other active substances to develop a series of medicinal and edible compositions for improving muscle attenuation. The composition disclosed by the invention has a good protective effect in improvement of old-age muscle attenuation, and can be applied to muscle attenuation and exercise ability decline accompanied by aging, so that the activity of telomerase is enhanced; meanwhile, the traditional Chinese medicine composition is helpful for adjusting the proportion of immune cell subtypes, improving functional activity decline of an immune system and reducing chronic low-level inflammation states, and has both safety and effectiveness. Molecular mechanism research shows that the compound activates glutathione metabolism and inhibits ferroptosis signals to reverse skeletal muscle cell senescence. The composition disclosed by the invention can be developed into foods and health-care products for improving muscle mass, volume, strength and functions, and has a very good application prospect.

The present invention relates to a pluripotent stem cell comprising an expression construct for expressing an MYOD protein and an expression construct for expressing an MYOG # protein. The invention further provides methods comprising the production of skeletal muscle cells using pluripotent stem cells and foods comprising skeletal muscle cells or pluripotent stem cells.

The present invention relates to a pluripotent stem cell comprising an expression construct for expressing an MYOD protein and an expression construct for expressing a PAX7 protein. The invention further provides methods comprising the production of skeletal muscle cells using pluripotent stem cells and foods comprising skeletal muscle cells or pluripotent stem cells.

The application relates to application of a recombinant protein to preparation of a medicine for inhibiting muscle atrophy, and belongs to the field of biological medicines. The application discloses application of a recombinant protein AGGF1 to preparation of a medicine for inhibiting muscle atrophy. The recombinant AGGF1 protein can inhibit mouse muscle atrophy (peripheral nerve injury muscle atrophy and cachexia muscle atrophy) and loss of skeletal muscle cell protein content. Therefore, the recombinant AGGF1 protein can be used for preparation of an anti-muscle atrophy medicine and treatment of muscle atrophy caused by lumbar intervertebral disc herniation and cachexia.

The present invention relates to the provision of a recombinant adeno-associated virus (rAAV)-based delivery vector comprising an oligopeptide insert having a length of at least 5 amino acids, which shows enhanced transduction efficiency in one or more muscle cells, in particular in cardiomyocytes and / or skeletal muscle cells. The rAAV vectors of the present disclosure are useful in the treatment and / or prevention of heart-related and / or muscle-related diseases or disorders and / or in gene therapy. The invention also provides methods of treating heart-related and / or muscle-related diseases or conditions.

The invention discloses a natural compound for inhibiting disulfide death by taking VAV3 as a target spot and application of the natural compound. Belongs to the technical field of biological medicine and pharmacy. According to the invention, through virtual screening and surface plasmon resonance technologies, seven small molecular compounds, including kaempferol, liensinine, sophocarpidine, isorhamnetin, deoxyshikonin, harmine and potenoside, which can be specifically bound with VAV3 protein are screened from a natural product library for the first time. In a C2C12 cell insulin resistance model, the compounds can significantly reduce the cell death rate caused by disulfide death, and the action mechanism of the compounds is to improve the activity or expression of VAV3, inhibit abnormal accumulation of cystine and improve the NADPH level, thereby effectively preventing disulfide bond crosslinking and collapse of an actin filament network. Experiments show that the compound provided by the invention can effectively inhibit disulfide death of skeletal muscle cells by targeting VAV3, and a new lead compound and a solution are provided for developing drugs for treating diabetic muscle dysfunction and related metabolic diseases.

The application describes methods for producing artificial skeletal muscle tissue from pluripotent stem cells. A method for producing skeletal myoblasts, skeletal myotubes and satellite cells from pluripotent stem cells is also disclosed. During the described methods, there is directed differentiation and maturation of the pluripotent stem cells into skeletal myotubes and satellite cells. The application also describes artificial skeletal muscle tissue which has multinuclear skeletal muscle fibres with satellite cells. Furthermore, the invention relates to mesodermally differentiated skeletal myoblast precursor cells, myogenically specified skeletal myoblast precursor cells, skeletal myoblast cells, satellite cells and skeletal myotubes, which can be produced by means of the disclosed methods. The application also describes the use of skeletal muscle tissue or the disclosed cells in drug testing or in medicine. Lastly, the application relates to in vitro methods in which the skeletal muscle tissue or the disclosed cells are used.

Provided herein are compositions comprising a muscle cell (cardiomyocyte and / or skeletal muscle cell) targeting peptide linked to the composition or inserted in a targeting protein of a recombinant vector having at least one exogenous peptide comprising Xn-RGD-n polymer-Xm. Compositions providing such conjugates, targeting peptides or recombinant vectors with engineered capsid or envelope proteins and uses thereof are provided.